Wolverine Trading
CHRS icon

Wolverine Trading’s Coherus Oncology CHRS Stock Holding History

Wolverine Trading’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$51.6K Buy
30,360
+12,657
+71% +$14.1K ﹤0.01% 5405
2025
Q2 		$13.2K Buy
17,703
+758
+4% +$654 ﹤0.01% 4489
2025
Q1 		$14.2K Buy
+16,945
New +$19.5K ﹤0.01% 4590
2024
Q2 		– Sell
-15,239
Closed -$30.7K – 4547
2024
Q1 		$36.4K Sell
15,239
-870
-5% -$2.14K ﹤0.01% 4270
2023
Q4 		$53.6K Sell
16,109
-2,399
-13% -$6.42K ﹤0.01% 4240
2023
Q3 		$69.2K Sell
18,508
-7,321
-28% -$33.8K ﹤0.01% 4103
2023
Q2 		$108K Buy
+25,829
New +$152K ﹤0.01% 3749
2023
Q1 		– Sell
-15,299
Closed -$119K – 4297
2022
Q4 		$121K Buy
+15,299
New +$118K ﹤0.01% 3355
2020
Q1 		– Sell
-20,912
Closed -$367K – 4681
2019
Q4 		$367K Buy
+20,912
New +$386K ﹤0.01% 3359
2017
Q4 		– Sell
-15,332
Closed -$164K – 4977
2017
Q3 		$205K Buy
15,332
+3,957
+35% +$52.3K ﹤0.01% 3772
2017
Q2 		$164K Buy
+11,375
New +$219K ﹤0.01% 3705

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wolverine Trading's CHRS Position: Q3 2025 in Review

Wolverine Trading increased its Coherus Oncology (CHRS) stake by 71% in Q3 2025, buying an estimated $14.1K and bringing the position to 30,360 shares worth $51.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5405.

Wolverine Trading first reported a position in CHRS in Q2 2017 and has held it in 11 quarters since. The position peaked at $367K in Q4 2019. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Wolverine Trading held 30,360 shares of Coherus Oncology worth $51.6K as of Q3 2025.
  • Wolverine Trading bought 12,657 Coherus Oncology shares in Q3 2025, an estimated $14.1K.
  • Coherus Oncology made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5405 holding.
  • Wolverine Trading first reported a position in Coherus Oncology in Q2 2017 and has held it in 11 quarters since.
  • Wolverine Trading's Coherus Oncology position peaked at $367K in Q4 2019.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.